



FORM PTO-1449/A and B (modified PTO/SB/08-06)

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

Sheet _____ of _____

APPLICATION NO.:	10/811,226	ATTY. DOCKET NO.:	C1041.70005US01
FILING DATE:	March 26, 2004	CONFIRMATION NO.:	1072
APPLICANT:	Hermann Wagner et al.		
GROUP ART UNIT:	Not Yet Assigned	EXAMINER:	Not Yet Assigned

U.S. PATENT DOCUMENTS

Examiner's Initials #	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or Issue of Cited Document MM-DD-YYYY
		Number	Kind Code		
/JZ/		6,030,954		Wu et al.	02-29-2000
		6,630,455	B1	Mitchell	10-07-2003
		6,620,805	B1	Takle et al.	09-16-2003
		7,129,222	B2	Van Nest et al.	10-31-2006
		2004-0157791	A1	Dow et al.	08-12-2004
		2005-0249794	A1	Semple et al.	11-10-2005
		2005-0181035	A1	Dow et al.	08-18-2005
		2006-0223769	A1	Dow et al.	10-05-2006

FOREIGN PATENT DOCUMENTS

Examiner's Initials #	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/ Country	Number	Kind Code			

OTHER ART – NON PATENT LITERATURE DOCUMENTS

Examiner's Initials #	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
/JZ/		BENNETT, Intracellular delivery of oligonucleotides with cationic liposomes. In: <i>Delivery Strategies for Antisense Oligonucleotide Therapeutics</i> . Akhtar, Ed. 1995:223-32.	
		COLEY PHARMACEUTICAL, Press Release, "Coley Pharmaceutical Group Updated Hepatitis C Drug Development Strategy," January 22, 2007	
		COLEY PHARMACEUTICAL, Press Release, "Coley Pharmaceutical Group announces Pfizer's Discontinuation of Clinical Trials for PF-3512676 Combined with Cytotoxic Chemotherapy in Advanced Non Small Cell Lung Cancer," June 20, 2007	
		CRYZ et al., European Commission COST/STD Initiative. Report of the expert panel VII. Vaccine delivery systems. <i>Vaccine</i> . 1996 May;14(7):665-90.	
		HUDSON et al., Nucleic acid dendrimers: Novel biopolymer structures. <i>J Am Chem Soc</i> . 1993;115:2119-24.	
		PISETSKY et al., The influence of base sequence on the immunological properties of defined oligonucleotides. <i>Immunopharmacology</i> . 1998 Nov;40(3):199-208	
		SONEHARA et al., Hexamer palindromic oligonucleotides with 5'-CG-3' motif(s) induce production of interferon. <i>J Interferon Cytokine Res</i> . 1996 Oct;16(10):799-803.	
		STEIN et al., Problems in interpretation of data derived from in vitro and in vivo use of antisense oligodeoxynucleotides. <i>Antisense Res Dev</i> . 1994 Summer;4(2):67-9.	

OTHER ART – NON PATENT LITERATURE DOCUMENTS

Examiner's Initials #	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
/JZ/		WAGNER et al., CpG motifs are efficient adjuvants for genetic vaccines to induce antigen-specific protective anti-tumor T cell responses. 2000;203:429. Abstract R46.	

EXAMINER:

/Jane Zara/

DATE CONSIDERED:

03/05/2009

[#] EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. ___, filed ___, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE – No copies of U.S. patents, published U.S. patent applications, or pending, unpublished patent applications stored in the USPTO's Image File Wrapper (IFW) system, are included. See 37 CFR §1.98 and 1287OG163. Copies of all other patent(s), publication(s), unpublished, pending U.S. patent applications, or other information listed are provided as required by 37 CFR §1.98 unless 1) such copies were provided in an IDS in an earlier application that complies with 37 CFR §1.98, and 2) the earlier application is relied upon for an earlier filing date under 35 U.S.C. §120.]